Cargando…

Overactive bladder in an integrated delivery system: a longitudinal cohort study

BACKGROUND: Overactive bladder (OAB) is common and morbid. Medication and diagnosis claims may be specific, but lack sensitivity to identify patients with overactive bladder. We used an “electronic health record (EHR) phenotype” to identify cases and describe treatment choices and anticholinergic bu...

Descripción completa

Detalles Bibliográficos
Autores principales: Linder, Jeffrey A., Weissman, Joel S., Reyes Nieva, Harry, Lipsitz, Stuart, Haring, R. Sterling, DeAngelis, Julie, Kristy, Rita M., Loughlin, Kevin R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238545/
https://www.ncbi.nlm.nih.gov/pubmed/32434511
http://dx.doi.org/10.1186/s12913-020-05315-1
_version_ 1783536552728592384
author Linder, Jeffrey A.
Weissman, Joel S.
Reyes Nieva, Harry
Lipsitz, Stuart
Haring, R. Sterling
DeAngelis, Julie
Kristy, Rita M.
Loughlin, Kevin R.
author_facet Linder, Jeffrey A.
Weissman, Joel S.
Reyes Nieva, Harry
Lipsitz, Stuart
Haring, R. Sterling
DeAngelis, Julie
Kristy, Rita M.
Loughlin, Kevin R.
author_sort Linder, Jeffrey A.
collection PubMed
description BACKGROUND: Overactive bladder (OAB) is common and morbid. Medication and diagnosis claims may be specific, but lack sensitivity to identify patients with overactive bladder. We used an “electronic health record (EHR) phenotype” to identify cases and describe treatment choices and anticholinergic burden for OAB. METHODS: We conducted a retrospective cohort study in a large, integrated health delivery system between July 2011 and June 2012 (2-year follow-up). We examined care from primary care and specialty clinics, medication and procedure use, and anticholinergic burden for each patient. RESULTS: There were 7362 patients with an EHR OAB phenotype; 50% of patients were > 65 years old, 74% were female, and 83% were white. The distribution of care included primary care physician (PCP)/specialty co-management (25% of patients); PCP care only (18%); urology only (13%); or some other combination of specialty care (33%). Only 40% of patients were prescribed at least 1 OAB medication during the study. The mean duration of prescribed medication was 1.5 months (95% confidence interval [CI], 1.4 to 1.6 months; range, < 1 month to 24 months). Independent predictors of receipt of an OAB medication included increasing age (odds ratio [OR], 1.4 for every 10 years; 95% CI, 1.4 to 1.5), women (OR, 1.6 compared with men; 95% CI, 1.4 to 1.8), diabetes (OR, 1.3; 95% CI, 1.1 to 1.5), and certain sources of care compared with PCP-only care: PCP/specialty co-management (OR, 1.8; 95% CI, 1.5 to 2.0), urology (OR, 2.2; 95% CI, 1.8 to 2.6), and multiple specialists (OR, 1.4; 95% CI, 1.2 to 1.8). Very few patients received other treatments: biofeedback (< 1%), onabotulinumtoxinA (2%), or sacral nerve stimulation (1%). Patients who received OAB medications had significantly higher anticholinergic burden than patients who did not (anticholinergic total standardized daily dose, 125 versus 46; P < .001). CONCLUSIONS: Although OAB is common and morbid, in a longitudinal study using an EHR OAB phenotype 40% of patients were treated with OAB medication and only briefly.
format Online
Article
Text
id pubmed-7238545
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72385452020-05-27 Overactive bladder in an integrated delivery system: a longitudinal cohort study Linder, Jeffrey A. Weissman, Joel S. Reyes Nieva, Harry Lipsitz, Stuart Haring, R. Sterling DeAngelis, Julie Kristy, Rita M. Loughlin, Kevin R. BMC Health Serv Res Research Article BACKGROUND: Overactive bladder (OAB) is common and morbid. Medication and diagnosis claims may be specific, but lack sensitivity to identify patients with overactive bladder. We used an “electronic health record (EHR) phenotype” to identify cases and describe treatment choices and anticholinergic burden for OAB. METHODS: We conducted a retrospective cohort study in a large, integrated health delivery system between July 2011 and June 2012 (2-year follow-up). We examined care from primary care and specialty clinics, medication and procedure use, and anticholinergic burden for each patient. RESULTS: There were 7362 patients with an EHR OAB phenotype; 50% of patients were > 65 years old, 74% were female, and 83% were white. The distribution of care included primary care physician (PCP)/specialty co-management (25% of patients); PCP care only (18%); urology only (13%); or some other combination of specialty care (33%). Only 40% of patients were prescribed at least 1 OAB medication during the study. The mean duration of prescribed medication was 1.5 months (95% confidence interval [CI], 1.4 to 1.6 months; range, < 1 month to 24 months). Independent predictors of receipt of an OAB medication included increasing age (odds ratio [OR], 1.4 for every 10 years; 95% CI, 1.4 to 1.5), women (OR, 1.6 compared with men; 95% CI, 1.4 to 1.8), diabetes (OR, 1.3; 95% CI, 1.1 to 1.5), and certain sources of care compared with PCP-only care: PCP/specialty co-management (OR, 1.8; 95% CI, 1.5 to 2.0), urology (OR, 2.2; 95% CI, 1.8 to 2.6), and multiple specialists (OR, 1.4; 95% CI, 1.2 to 1.8). Very few patients received other treatments: biofeedback (< 1%), onabotulinumtoxinA (2%), or sacral nerve stimulation (1%). Patients who received OAB medications had significantly higher anticholinergic burden than patients who did not (anticholinergic total standardized daily dose, 125 versus 46; P < .001). CONCLUSIONS: Although OAB is common and morbid, in a longitudinal study using an EHR OAB phenotype 40% of patients were treated with OAB medication and only briefly. BioMed Central 2020-05-20 /pmc/articles/PMC7238545/ /pubmed/32434511 http://dx.doi.org/10.1186/s12913-020-05315-1 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Linder, Jeffrey A.
Weissman, Joel S.
Reyes Nieva, Harry
Lipsitz, Stuart
Haring, R. Sterling
DeAngelis, Julie
Kristy, Rita M.
Loughlin, Kevin R.
Overactive bladder in an integrated delivery system: a longitudinal cohort study
title Overactive bladder in an integrated delivery system: a longitudinal cohort study
title_full Overactive bladder in an integrated delivery system: a longitudinal cohort study
title_fullStr Overactive bladder in an integrated delivery system: a longitudinal cohort study
title_full_unstemmed Overactive bladder in an integrated delivery system: a longitudinal cohort study
title_short Overactive bladder in an integrated delivery system: a longitudinal cohort study
title_sort overactive bladder in an integrated delivery system: a longitudinal cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238545/
https://www.ncbi.nlm.nih.gov/pubmed/32434511
http://dx.doi.org/10.1186/s12913-020-05315-1
work_keys_str_mv AT linderjeffreya overactivebladderinanintegrateddeliverysystemalongitudinalcohortstudy
AT weissmanjoels overactivebladderinanintegrateddeliverysystemalongitudinalcohortstudy
AT reyesnievaharry overactivebladderinanintegrateddeliverysystemalongitudinalcohortstudy
AT lipsitzstuart overactivebladderinanintegrateddeliverysystemalongitudinalcohortstudy
AT haringrsterling overactivebladderinanintegrateddeliverysystemalongitudinalcohortstudy
AT deangelisjulie overactivebladderinanintegrateddeliverysystemalongitudinalcohortstudy
AT kristyritam overactivebladderinanintegrateddeliverysystemalongitudinalcohortstudy
AT loughlinkevinr overactivebladderinanintegrateddeliverysystemalongitudinalcohortstudy